A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers

Yuan C Ding, Lesley McGuffog, Sue Healey, Eitan Friedman, Yael Laitman, Shani- Paluch-Shimon, Bella Kaufman, Annelie Liljegren, Annika Lindblom, Håkan Olsson, Ulf Kristoffersson, Marie Stenmark-Askmalm, Beatrice Melin, Susan M Domchek, Katherine L Nathanson, Timothy R Rebbeck, Anna Jakubowska, Jan Lubinski, Katarzyna Jaworska, Katarzyna DurdaJacek Gronwald, Tomasz Huzarski, Cezary Cybulski, Tomasz Byrski, Ana Osorio, Teresa Ramóny Cajal, Alexandra V Stavropoulou, Javier Benítez, Ute Hamann, Matti Rookus, Cora M Aalfs, Judith L de Lange, Hanne E J Meijers-Heijboer, Jan C Oosterwijk, Christi J van Asperen, Encarna B Gómez García, Nicoline Hoogerbrugge, Agnes Jager, Rob B van der Luijt, Douglas F Easton, Susan Peock, Debra Frost, Steve D Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Fiona Lalloo, Thomas V O Hansen, Bent Ejlertsen, Anne-Marie Gerdes, SWE-BRCA

19 Citationer (Scopus)

Abstract

We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2 mutation carriers.
OriginalsprogEngelsk
TidsskriftCancer Epidemiology, Biomarkers & Prevention
Vol/bind21
Udgave nummer8
Sider (fra-til)1362-70
Antal sider9
ISSN1055-9965
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers'. Sammen danner de et unikt fingeraftryk.

Citationsformater